- Oral presentation
- Open access
- Published:
Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study
Retrovirology volume 3, Article number: S15 (2006)
Anti-Tat therapeutic vaccination has been clinically investigated by different groups [1–4], given that 1) extracellular Tat protein induces T cell apoptosis and cellular immune suppression, 2) epidemiological data showed that LTNP exhibit high level of serum anti-Tat Ab, negatively correlated with p24 antigenemia, 3) in Tat immunized macaques, viremia decreased following SHIV challenge. Anti-Tat therapeutic vaccination using Tat Toxoid adjuvanted either with Seppic [1, 2] or with alum or DcChol (Aventis Pasteur) proved to be safe. A prospective structured treatment interruption study (STI) monitored according to EU guidelines was conducted at Hospital St-Pierre, Brussels (Pr. N. Clumeck) on 31 vaccinees who received a DcChol adjuvanted Tat Toxoid (n = 12), a DcChol placebo (n = 8) or non adjuvanted Tat toxoid (n = 11). The 2 year study follow-up showed that vaccinees developing high titer of Abs neutralizing Tat bioactivity prolonged HAART-interruption.
References
Gringeri A, Santagostino E, Muca-Perja M, Mannucci PM, Zagury JF, Bizzini B, Lachgar A, Carcagno M, Rappaport J, Criscuolo M, Blattner W, Burny A, Gallo RC, Zagury D: Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol. 1988, 1: 293-298.
Gringeri A, Santagostino E, Muca-Perja M, Le Buanec H, Bizzini B, Lachgar A, Zagury JF, Rappaport J, Burny A, Gallo RC, Zagury D: Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999, 20: 371-375.
Caputo A, Gavioli R, Ensoli B: Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res. 2004, 2: 357-376. 10.2174/1570162043350986.
Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman DM, Weinhold KJ, Sandstrom E, Wahren B: Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol. 1999, 163: 2330-2338.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Clumeck, N., Hermans, P., Zagury, D. et al. Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study. Retrovirology 3 (Suppl 1), S15 (2006). https://doi.org/10.1186/1742-4690-3-S1-S15
Published:
DOI: https://doi.org/10.1186/1742-4690-3-S1-S15